FR2527444B1 - Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite - Google Patents
Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxiciteInfo
- Publication number
- FR2527444B1 FR2527444B1 FR8308586A FR8308586A FR2527444B1 FR 2527444 B1 FR2527444 B1 FR 2527444B1 FR 8308586 A FR8308586 A FR 8308586A FR 8308586 A FR8308586 A FR 8308586A FR 2527444 B1 FR2527444 B1 FR 2527444B1
- Authority
- FR
- France
- Prior art keywords
- refined
- toxicity
- composition containing
- therapeutic composition
- endotoxin free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002158 endotoxin Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- 229930186217 Glycolipid Natural products 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000006227 byproduct Substances 0.000 abstract 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 abstract 1
- 231100000284 endotoxic Toxicity 0.000 abstract 1
- 230000002346 endotoxic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/382,406 US4435386A (en) | 1982-05-26 | 1982-05-26 | Refined detoxified endotoxin product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2527444A1 FR2527444A1 (fr) | 1983-12-02 |
| FR2527444B1 true FR2527444B1 (fr) | 1987-02-20 |
Family
ID=23508812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8308586A Expired FR2527444B1 (fr) | 1982-05-26 | 1983-05-25 | Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4435386A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS58222027A (cg-RX-API-DMAC7.html) |
| CA (1) | CA1225591A (cg-RX-API-DMAC7.html) |
| DE (1) | DE3318568C2 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2527444B1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2122084B (cg-RX-API-DMAC7.html) |
| IT (1) | IT1164244B (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4505899A (en) * | 1982-05-26 | 1985-03-19 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| CA1225592A (en) * | 1983-08-26 | 1987-08-18 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| US4497730A (en) * | 1984-04-03 | 1985-02-05 | The United States Of America As Represented By The Department Of Health And Human Services | Method for obtaining periplasmic proteins from bacterial cells using chloroform |
| NL8401226A (nl) * | 1984-04-16 | 1985-11-18 | Univ Utrecht | Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie. |
| US4629722A (en) * | 1984-07-12 | 1986-12-16 | Ribi Immunochem Research, Inc. | Method of inhibiting the onset of acute radiation syndrome |
| US4929604A (en) * | 1986-05-28 | 1990-05-29 | Board Of Regents, The University Of Texas System | Lipopolysaccharides of reduced toxicity and the production thereof |
| US4845036A (en) * | 1987-02-03 | 1989-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Process for isolation of the B oligomer of pertussis toxin |
| US5416070A (en) * | 1988-07-08 | 1995-05-16 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| US4950645A (en) * | 1988-07-08 | 1990-08-21 | Immunotherapeutics, Inc. | Composition for macrophage activation |
| US6218166B1 (en) | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| WO1998035665A1 (fr) * | 1997-02-14 | 1998-08-20 | Ajinomoto Co., Inc. | Antagonistes des endotoxines |
| AU4057300A (en) | 1999-03-30 | 2000-10-16 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinacious compounds |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US20030224013A1 (en) * | 2002-04-19 | 2003-12-04 | Cole Garry T. | Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein |
| NZ574146A (en) | 2002-07-15 | 2010-05-28 | Univ Texas | Peptides binding to phosphatidylethanolamine and their use in treating viral infections |
| WO2008094183A2 (en) * | 2006-07-11 | 2008-08-07 | University Of Connecticut | Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination |
| EP2477652B1 (en) | 2009-09-16 | 2015-04-15 | Vaxart, Inc. | Immunization strategy to prevent h1n1 infection |
| HK1214510A1 (zh) | 2013-04-18 | 2016-07-29 | Immune Design Corp. | 用於癌症治疗的gla单一疗法 |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| SG10201802194WA (en) | 2013-09-19 | 2018-05-30 | Novavax Inc | Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods |
| IL247301B (en) | 2014-02-20 | 2022-07-01 | Vaxart Inc | Formulations for small intestinal delivery |
| CA2988761A1 (en) | 2015-06-12 | 2016-12-15 | Vaxart, Inc. | Formulations for small intestinal delivery of rsv and norovirus antigens |
| EP3423044A4 (en) | 2016-03-02 | 2019-11-20 | The Board of Regents of The University of Texas System | STING-ACTIVATING NANO VACCINE FOR IMMUNOTHERAPY |
| AU2017294751B2 (en) | 2016-07-13 | 2023-10-05 | Ohio State Innovation Foundation | Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity |
| US11376320B2 (en) | 2020-03-05 | 2022-07-05 | Iowa State University Research Foundation, Inc. | Immunogenic and vaccine compositions against SARS-CoV-2 |
-
1982
- 1982-05-26 US US06/382,406 patent/US4435386A/en not_active Expired - Lifetime
-
1983
- 1983-05-12 GB GB08313054A patent/GB2122084B/en not_active Expired
- 1983-05-20 DE DE3318568A patent/DE3318568C2/de not_active Expired
- 1983-05-24 CA CA000428677A patent/CA1225591A/en not_active Expired
- 1983-05-25 FR FR8308586A patent/FR2527444B1/fr not_active Expired
- 1983-05-25 IT IT21289/83A patent/IT1164244B/it active
- 1983-05-25 JP JP58090858A patent/JPS58222027A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB2122084B (en) | 1986-02-05 |
| GB8313054D0 (en) | 1983-06-15 |
| US4435386A (en) | 1984-03-06 |
| IT1164244B (it) | 1987-04-08 |
| IT8321289A0 (it) | 1983-05-25 |
| JPS58222027A (ja) | 1983-12-23 |
| DE3318568A1 (de) | 1984-01-12 |
| GB2122084A (en) | 1984-01-11 |
| DE3318568C2 (de) | 1987-01-15 |
| FR2527444A1 (fr) | 1983-12-02 |
| CA1225591A (en) | 1987-08-18 |
| JPS6234730B2 (cg-RX-API-DMAC7.html) | 1987-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2527444B1 (fr) | Composition therapeutique contenant une endotoxine raffinee debarrassee de sa toxicite | |
| FR2527443B1 (fr) | Composition contenant de l'endotoxine raffinee et medicament la contenant | |
| BR0112542A (pt) | Composições e métodos papa a terapia e a diagnose de câncer ovariano | |
| NO931843D0 (no) | Legemiddelavgivende porfyrinpreparater og fremgangsmaater | |
| WO1992002240A3 (en) | Novel methods and compositions for treatment of angiogenic diseases | |
| FI935174A0 (fi) | Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem | |
| KR970704410A (ko) | 암 치료용 종양 세포를 함유하는 이식 장치(Implanted Device Containing Tumor Cells for the Treatment of Cancer) | |
| EP0184040A3 (en) | Method and system for removing immunosuppressive components from the blood of mammals | |
| SE8000435L (sv) | N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning | |
| GR78462B (cg-RX-API-DMAC7.html) | ||
| GB2276623A (en) | Cytotoxic drug therapy | |
| FR2406641A1 (fr) | 2,6-diaminonebularines et leur application therapeutique | |
| SE8404707L (sv) | Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav | |
| ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
| NO932101D0 (no) | Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker | |
| SE8302519D0 (sv) | Solfilterkompositioner | |
| SE8404283L (sv) | Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar | |
| ES2086651T3 (es) | Nuevos compuestos, denominados "leustroducsinas", su preparacion y sus utilizaciones terapeuticas. | |
| KR890700353A (ko) | 면역독소의 면역억제 기저 사람치료법 | |
| SE7905810L (sv) | Spiroketaliner och deras anvendningar | |
| DK225689D0 (da) | Anvendelse af metalloporphyriner til modvirkning af den toksiske virkning af tumorterapi | |
| FR2423223A1 (fr) | Vaccin et dose a injecter pour l'immunotherapie d'une maladie neoplasique | |
| IT1065996B (it) | Agente per la diagnosi precoce del cancro e relativo procedimento di applicazione | |
| Apelgot et al. | Differences in the consequences of the decay of radioactive64Cu atoms incorporated in cells under either in vitro or in vivo conditions | |
| Prichard-Thomas et al. | The use of immunologically competent cells from pig mesenteric lymph nodes to treat pulmonary tumors in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ER | Errata listed in the french official journal (bopi) |
Free format text: 48/83 |
|
| ST | Notification of lapse |